Ribosomal protein L17 pseudogene 22 (RPL17P22)

Ribosomal protein L17 pseudogene 22 (RPL17P22) is a processed pseudogene in the human genome, meaning it is a DNA segment derived from the functional RPL17 gene, but does not produce a functional protein due to disabling mutations or sequence truncations[5][8][9][10]. Pseudogenes like RPL17P22 are remnants from retrotransposition or gene duplication events and are generally viewed as nonfunctional genetic elements. While some pseudogenes can be transcribed or, in rare cases, translated into peptides[4], there is no evidence that RPL17P22 has any biological role, therapeutic relevance, or disease association. It should not be considered a therapeutic target, receptor, enzyme, or biomarker, and its use in such contexts would be scientifically inaccurate[5][8][9][10]. Key distinctions: - The parental gene, RPL17, encodes a ribosomal protein essential for normal cellular function, while RPL17P22 does not encode any active product[1][3][5][7][15]. - RPL17P22 is classified as a processed pseudogene, and—like most human pseudogenes—shows no functional protein, no known pathological implications, and no suitability for targeting with drugs or therapies[5][8][9][10].

Other names

RPL17P22RPL17_13_564RPL17P22 (as per various databases)Ribosomal protein L17 pseudogene 22